Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 6Neuroendocrine Tumors 2Urogenital Neoplasms 1Prostatic Diseases 1Oligometastatic Prostate Cancer (OMPC) 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Cisplatin 15pembrolizumab 14Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 10Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Paclitaxel 7durvalumab 6Radiotherapy, Intensity-Modulated 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Pemetrexed 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3ipatasertib 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Lutetium-177 × 90 days × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡